These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 12469001)
1. Tetrabenazine treatment for Huntington's disease-associated chorea. Ondo WG; Tintner R; Thomas M; Jankovic J Clin Neuropharmacol; 2002; 25(6):300-2. PubMed ID: 12469001 [TBL] [Abstract][Full Text] [Related]
2. Treatment of chorea associated with Huntington's disease: focus on tetrabenazine. Setter SM; Neumiller JJ; Dobbins EK; Wood L; Clark J; DuVall CA; Santiago A Consult Pharm; 2009 Jul; 24(7):524-37. PubMed ID: 19689181 [TBL] [Abstract][Full Text] [Related]
3. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Chen JJ; Ondo WG; Dashtipour K; Swope DM Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259 [TBL] [Abstract][Full Text] [Related]
4. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. Frank S BMC Neurol; 2009 Dec; 9():62. PubMed ID: 20021666 [TBL] [Abstract][Full Text] [Related]
5. An experimental model for Huntington's chorea? Zeef DH; Jahanshahi A; Vlamings R; Casaca-Carreira J; Santegoeds RG; Janssen ML; Oosterloo M; Temel Y Behav Brain Res; 2014 Apr; 262():31-4. PubMed ID: 24412685 [TBL] [Abstract][Full Text] [Related]
6. The long-term effect of tetrabenazine in the management of Huntington disease. Fasano A; Cadeddu F; Guidubaldi A; Piano C; Soleti F; Zinzi P; Bentivoglio AR Clin Neuropharmacol; 2008; 31(6):313-8. PubMed ID: 19050408 [TBL] [Abstract][Full Text] [Related]
7. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Frank S; Ondo W; Fahn S; Hunter C; Oakes D; Plumb S; Marshall F; Shoulson I; Eberly S; Walker F; Factor S; Hunt V; Shinaman A; Jankovic J Clin Neuropharmacol; 2008; 31(3):127-33. PubMed ID: 18520979 [TBL] [Abstract][Full Text] [Related]
8. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Jankovic J; Clarence-Smith K Expert Rev Neurother; 2011 Nov; 11(11):1509-23. PubMed ID: 22014129 [TBL] [Abstract][Full Text] [Related]
9. Impact of tetrabenazine on gait and functional mobility in individuals with Huntington's disease. Kegelmeyer DA; Kloos AD; Fritz NE; Fiumedora MM; White SE; Kostyk SK J Neurol Sci; 2014 Dec; 347(1-2):219-23. PubMed ID: 25456459 [TBL] [Abstract][Full Text] [Related]
16. Management of Huntington's disease: role of tetrabenazine. de Tommaso M; Serpino C; Sciruicchio V Ther Clin Risk Manag; 2011; 7():123-9. PubMed ID: 21479143 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Furr Stimming E; Claassen DO; Kayson E; Goldstein J; Mehanna R; Zhang H; Liang GS; Haubenberger D; Lancet Neurol; 2023 Jun; 22(6):494-504. PubMed ID: 37210099 [TBL] [Abstract][Full Text] [Related]
18. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. ; Frank S; Testa CM; Stamler D; Kayson E; Davis C; Edmondson MC; Kinel S; Leavitt B; Oakes D; O'Neill C; Vaughan C; Goldstein J; Herzog M; Snively V; Whaley J; Wong C; Suter G; Jankovic J; Jimenez-Shahed J; Hunter C; Claassen DO; Roman OC; Sung V; Smith J; Janicki S; Clouse R; Saint-Hilaire M; Hohler A; Turpin D; James RC; Rodriguez R; Rizer K; Anderson KE; Heller H; Carlson A; Criswell S; Racette BA; Revilla FJ; Nucifora F; Margolis RL; Ong M; Mendis T; Mendis N; Singer C; Quesada M; Paulsen JS; Brashers-Krug T; Miller A; Kerr J; Dubinsky RM; Gray C; Factor SA; Sperin E; Molho E; Eglow M; Evans S; Kumar R; Reeves C; Samii A; Chouinard S; Beland M; Scott BL; Hickey PT; Esmail S; Fung WL; Gibbons C; Qi L; Colcher A; Hackmyer C; McGarry A; Klos K; Gudesblatt M; Fafard L; Graffitti L; Schneider DP; Dhall R; Wojcieszek JM; LaFaver K; Duker A; Neefus E; Wilson-Perez H; Shprecher D; Wall P; Blindauer KA; Wheeler L; Boyd JT; Houston E; Farbman ES; Agarwal P; Eberly SW; Watts A; Tariot PN; Feigin A; Evans S; Beck C; Orme C; Edicola J; Christopher E JAMA; 2016 Jul; 316(1):40-50. PubMed ID: 27380342 [TBL] [Abstract][Full Text] [Related]
19. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Ondo WG; Hanna PA; Jankovic J Am J Psychiatry; 1999 Aug; 156(8):1279-81. PubMed ID: 10450276 [TBL] [Abstract][Full Text] [Related]
20. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders. Koch J; Shi WX; Dashtipour K Pharmacol Ther; 2020 Aug; 212():107580. PubMed ID: 32454050 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]